The Discussion is the section where your study earns its contribution to the field. It is where you explain what your results mean, how they relate to existing knowledge, where their limits lie, and why they matter. A strong Results section followed by a weak Discussion leaves reviewers thinking: “The data are fine, but the authors do not understand what they found.”

These five mistakes appear across Discussion sections in medical and life science manuscripts. Each weakens the interpretive value of the section and gives reviewers a reason to request major revisions.

1. Repeating Results Instead of Interpreting Them

The most common Discussion mistake is opening with a restatement of the Results. Authors summarize their findings using slightly different words, but add no new interpretation, no comparison with prior work, and no explanation of mechanisms. Reviewers recognize this immediately: if the first paragraph of the Discussion reads like a condensed version of the Results section, the author has not yet begun to discuss.

Typical original:

In this study, we found that patients in the treatment group had significantly lower HbA1c levels compared with the control group (6.8% vs. 7.9%, p < 0.01). The treatment group also showed improved fasting glucose levels and reduced insulin resistance.

Revised:

The reduction in HbA1c levels observed in the treatment group (6.8% vs. 7.9%, p < 0.01) is consistent with prior reports of SGLT2 inhibitor efficacy in type 2 diabetes management. Notably, the magnitude of this reduction (1.1 percentage points) exceeds the 0.5-point change commonly accepted as clinically meaningful in glycemic control, suggesting that this intervention may offer benefits beyond those achieved by existing first-line therapies.

The revised version begins with the same result but immediately places it in context: it compares the finding to prior literature, quantifies its clinical relevance, and suggests what it might mean for treatment decisions. This is interpretation.

2. Ignoring Studies That Contradict Your Findings

When prior studies have reported results that conflict with yours, ignoring them does not make the conflict disappear. Reviewers know the literature. If a well-cited study found the opposite of what you found, and your Discussion does not mention it, the reviewer will either assume you are unaware of the study or that you are deliberately avoiding an inconvenient comparison. Both assumptions damage credibility.

Addressing contradictory evidence is not a weakness. It is a demonstration of scientific maturity.

Typical original:

Our results are consistent with previous studies showing that high vitamin D levels are associated with reduced fracture risk in postmenopausal women (Smith et al., 2020; Lee et al., 2021).

(No mention of the VITAL trial or other large studies that found no significant association.)

Revised:

Our results are consistent with observational studies reporting an inverse association between vitamin D levels and fracture risk in postmenopausal women (Smith et al., 2020; Lee et al., 2021). However, our findings contrast with those of the VITAL randomized trial, which found no significant reduction in fracture incidence with vitamin D supplementation in a general population cohort (LeBoff et al., 2022). This discrepancy may reflect differences in study population (our cohort included only women with documented vitamin D deficiency) and supplementation dosing (our protocol used 4,000 IU daily versus 2,000 IU in VITAL). These differences suggest that the protective effect of vitamin D supplementation may be concentration-dependent and limited to deficient populations.

The revised version acknowledges the contradictory study, explains the specific differences in design that may account for the discrepancy, and uses the comparison to sharpen the interpretation of the current results.

3. Listing Limitations Without Explaining Their Impact

Most authors know that a limitations paragraph is expected. The problem is that many treat it as a formality: they list potential weaknesses without explaining how each limitation affects the interpretation of results. A limitations paragraph that reads like a checklist without analysis suggests the authors included it only because they were told to.

Typical original:

This study has several limitations. First, the sample size was relatively small. Second, it was a single-center study. Third, the follow-up period was short. Fourth, we did not include a placebo control.

Revised:

This study has several limitations that affect the generalizability of our findings. The sample size (n = 86) may have been insufficient to detect small but clinically meaningful differences in secondary endpoints, particularly the subgroup analysis of patients over 65 years. As a single-center study conducted at a tertiary referral hospital, the patient population may not represent community-level disease severity, and the intervention’s effectiveness in primary care settings remains to be established. The 6-month follow-up period captures short-term treatment response but cannot address long-term durability of benefit or late-emerging adverse effects.

The revised version explains the consequence of each limitation. The sample size is not just “small”; it may have missed effects in a specific subgroup. The single-center design is not just a limitation; it affects generalizability to a specific clinical context. Each limitation is linked to a concrete interpretive consequence.

4. Overgeneralizing From Limited Data

A single-center, retrospective study of 120 patients cannot support claims about “all patients with this condition.” A cell culture experiment cannot predict clinical outcomes. An observational study cannot establish causation. Yet Discussion sections routinely extend conclusions beyond what the study design can support.

This mistake is distinct from overclaiming in the Results section (which we covered in a previous post). In the Discussion, overgeneralization occurs when authors broaden the scope of their interpretation to populations, settings, or mechanisms that their study did not directly examine.

Typical original:

Based on our findings, this biomarker should be incorporated into routine clinical screening for early detection of pancreatic cancer.

Revised:

Our findings suggest that this biomarker warrants further investigation as a potential screening tool for pancreatic cancer. Validation in a larger, multicenter prospective cohort is needed to establish its diagnostic accuracy across different disease stages and patient demographics before clinical implementation can be considered.

The revised version maintains the positive implication of the findings while clearly specifying what additional steps are needed before a clinical recommendation is justified. The language shifts from “should be incorporated” (a definitive recommendation) to “warrants further investigation” (an appropriate next step given the evidence).

5. Ending Without a Clear Statement of Significance or Future Direction

The final paragraph of the Discussion is the last impression the reviewer carries into their evaluation. When it trails off with a vague restatement (“In conclusion, our study found that
”) or ends abruptly after the limitations, the manuscript feels incomplete.

An effective closing paragraph does two things: it states the practical or theoretical significance of the work (what does this mean for the field?), and it identifies specific, actionable directions for future research (what should be done next?).

Typical original:

In conclusion, our study found that treatment X was associated with improved outcomes in patients with condition Y. Further studies are needed to confirm these findings.

Revised:

These findings position treatment X as a candidate adjunct therapy for patients with condition Y who do not respond adequately to standard first-line management. Two specific questions merit investigation in future trials: whether the treatment effect persists beyond the 12-month observation window examined here, and whether the benefit extends to patients with comorbid condition Z, a population excluded from the current study.

The revised version specifies who might benefit (non-responders to first-line therapy), identifies two concrete research questions, and links them to specific gaps in the current study. “Further studies are needed” is replaced by a clear research agenda.

Checklist Before Submitting Your Discussion

  1. Does the opening paragraph of your Discussion interpret your results or merely restate them? If you can swap it with a paragraph from your Results section, it needs rewriting.
  2. Have you addressed published studies that found different results from yours? Have you explained why the discrepancies might exist?
  3. For each limitation listed, have you explained its specific impact on your results or their interpretation?
  4. Do your conclusions stay within the boundaries of your study design? Single-center studies support hypotheses; they do not establish universal recommendations.
  5. Does the final paragraph state the practical significance of your work and identify specific, testable questions for future research?

A well-crafted Discussion transforms data into understanding. It is the section that separates a publishable manuscript from one that needs major revision. If you want expert feedback on whether your Discussion makes the case your data deserve, ScholarMemory provides professional editing for medical and life science researchers. Contact us at contact@scholarmemory.com.